In recent years, Brazil has intensified its efforts to strengthen the innovation environment in healthcare, with remarkable advances in the pharmaceutical and biotechnology sectors. These areas are essential for economic development and for positioning the country as a competitive leader on the global stage. The latest report from the World Intellectual Property Organization (WIPO), titled World Intellectual Property Report 2024, offers valuable insights into global and regional progress in the use of Intellectual Property (IP) as a driver of innovation, especially in emerging economies. Brazil stands out as one of the economies that seeks, through incentive policies and IP protection, to advance in the complex field of healthcare.
The Importance of Intellectual Property in Innovation Growth
According to recent data from the National Institute of Industrial Property (INPI), Brazil has seen a substantial increase in pharmaceutical patent applications in recent years, growing from 117 in 2006 to 334 in 2020. This growth is not just a statistic but reflects a movement towards endogenous innovation, where Brazilian institutions and companies are focused on developing solutions tailored to the country’s reality. In the biotechnology sector, which includes advanced therapies, genomics, and immunotherapies, Brazil also shows strong performance, although it faces structural and infrastructure challenges in translating these innovations into widely accessible commercial products.
These advances in patents are essential for Brazilian companies to ensure a return on investment in research and development (R&D). According to the WIPO report, IP is especially relevant in sectors with high innovation costs, such as the pharmaceutical and biotechnology industries, where the development cycle is long and requires robust protection to introduce new technologies with safety and competitiveness.
Strengthening Research Capacity in Health and Pharmaceuticals
In Brazil, Fiocruz and the Instituto Butantan have been leaders in developing vaccines, personalized therapies, and biotechnological solutions. These institutions not only represent Brazil's scientific capacity but also establish international collaborations that enhance local innovation. During the COVID-19 pandemic, for example, these institutions were crucial in Brazil’s response, developing vaccines and forming partnerships for local manufacturing. These initiatives demonstrated the importance of strategic partnerships between the public and private sectors in addressing global health crises.
Moreover, Brazil’s regulatory environment has been keeping pace with this innovation trajectory, with policies that seek to align the industry’s long-term interests with the need for IP protection. The National Health Surveillance Agency (Anvisa) has played a significant role in supporting health innovation by providing regulatory support and collaborating with INPI to accelerate patent approvals in strategic areas, such as medicines and medical devices.
Opportunities and Regional Competitiveness Challenges
In the Latin American context, Brazil stands out as one of the countries with the most developed health innovation ecosystems. This position is the result of a series of policies encouraging research and innovation, as well as a relatively advanced R&D infrastructure. However, the country still faces obstacles that limit its ability to compete globally. One of the biggest challenges is the dependence on imported inputs for drug manufacturing. Around 90% of the active pharmaceutical ingredients (APIs) used by the national industry are imported, which represents a significant vulnerability during supply chain disruptions.
To overcome this challenge, Brazil will need to strengthen its capacity for local production of pharmaceutical inputs and invest in infrastructure that supports innovation scalability. Federal government initiatives, such as the Brasil Mais Produtivo program, which aims to stimulate the production of essential inputs, are important steps in this direction, but there is still a long way to go to achieve significant independence. Supporting public-private partnerships, such as those established in the agricultural biotechnology sector, could be a viable solution to boost local production in the health sector as well.
Comparison with Other Emerging Economies
On the global stage, countries like India and China have excelled in pharmaceutical and biotechnology innovation. India, for instance, has become a global hub for the production of generic medicines and vaccines, thanks to an innovation incentive policy that offers tax benefits and subsidies for R&D. China, on the other hand, has heavily invested in its research infrastructure and IP protection, promoting an environment that favors the creation of locally developed technologies that compete globally.
Although Brazil has a solid R&D base, it still needs to progress in terms of infrastructure and production capacity to reach the level of these countries. However, Brazil’s experience with collaborative innovation and its leadership in Latin America offer an interesting model for other emerging economies. Brazilian institutions such as the Instituto Butantan and Fiocruz already exercise regional influence, exporting innovation to other Latin American countries and forming collaborative research networks that promote the sharing of knowledge and technology.
Strategies for the Future of Health Innovation in Brazil
For Brazil to continue advancing, some strategies are essential:
Strengthening National Production: Investing in infrastructure for API production and technologies that reduce dependence on imported inputs. This will not only increase sector resilience but also promote the competitiveness of Brazilian companies in the global market.
Expanding Strategic Partnerships: Creating public-private partnerships to drive the development of local technologies is essential. These partnerships can facilitate cost-sharing in R&D, reduce risks for companies, and accelerate the development of innovative solutions.
Encouraging IP Protection: IP protection should be seen as a long-term strategy to strengthen Brazil's position in the global innovation landscape. Strengthening cooperation between INPI and Anvisa to expedite patent approvals in strategic areas can provide legal certainty for companies and attract investments.
Supporting Regional Innovation: Encouraging innovation hubs in different regions of the country, leveraging local resources and expertise to create a more diverse and resilient ecosystem. These hubs can promote local and regional innovation, expanding the economic and social impact of the health sector in Brazil.
Building the Future of Health Innovation with IBIS
The Brazilian Health Innovation Institute - IBIS is committed to this vision of growth and strengthening of the health innovation ecosystem in Brazil. We work to inspire and empower entrepreneurs, researchers, and startups, offering support and connecting key players to turn ideas into real solutions that impact people’s lives. Our mission is to contribute to an innovation environment that promotes competitiveness and sustainability in the health sector.
Want to know more about our initiatives and how IBIS is shaping the future of health innovation in Brazil? Visit our website and follow our actions to become part of this movement.
To access the full WIPO report, please refer to this link.
by Marcio de Paula
Brazilian Health Innovation Institute - IBIS
Comments